Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
Compose a Response to This Article
Other responses
No responses have been published for this article.
